PPAR Research

Volume 2012 (2012), Article ID 383829, 7 pages

doi:10.1155/2012/383829

Review Article

PPARγ Expression and Function in Mycobacterial Infection: Roles in Lipid Metabolism, Immunity, and Bacterial Killing

Patricia E. Almeida,1,2 Alan Brito Carneiro,¹ Adriana R. Silva,¹ and Patricia T. Bozza¹

¹Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, 21045-900 Rio de Janeiro, RJ, Brazil

²Laboratório de Biologia Celular, Departamento de Biologia, Universidade Federal de Juiz de Fora, 36036-900 Juiz de Fora, MG, Brazil

Received 14 January 2012; Revised 30 March 2012; Accepted 18 May 2012

Academic Editor: Jesse Roman

Copyright © 2012 Patricia E. Almeida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Tuberculosis continues to be a global health threat, with drug resistance and HIV coinfection presenting challenges for its control. Mycobacterium tuberculosis, the etiological agent of tuberculosis, is a highly adapted pathogen that has evolved different strategies to subvert the immune and metabolic responses of host cells. Although the significance of peroxisome proliferator-activated receptor gamma (PPAR) activation by mycobacteria is not fully understood, recent findings are beginning to uncover a critical role for PPAR during mycobacterial infection. Here, we will review the molecular mechanisms that regulate PPAR expression and function during mycobacterial infection. Current evidence indicates that mycobacterial infection causes a time-dependent increase in PPAR expression through mechanisms that involve pattern recognition receptor activation. Mycobacterial triggered increased PPAR expression and activation lead to increased lipid droplet formation and downmodulation of macrophage response, suggesting that PPAR expression might aid the mycobacteria in circumventing the host response acting as an escape mechanism. Indeed, inhibition of PPAR enhances mycobacterial killing capacity of macrophages, suggesting a role of PPAR in favoring the establishment of chronic infection. Collectively, PPAR is emerging as a regulator of tuberculosis pathogenesis and an attractive target for the development of adjunctive tuberculosis therapies.

1. Introduction

Tuberculosis is a global public health problem, with over 9 million new cases being reported each year that are responsible for almost 2 million deaths annually worldwide [1]. Mycobacterium  tuberculosis (M. tuberculosis), the etiological agent of tuberculosis, is a highly successful pathogen, infecting approximately one-third of the human population, and it has adapted to live within the hostile macrophage environment. Through long-standing coevolution with its mammalian host, M. tuberculosis has evolved different strategies to subvert the immune and metabolic responses of the host cells. Pathogenic species of mycobacteria express and regulate numerous genes within the host to evade the host immune responses and suit their intracellular life style. Among the intracellularly induced genes, several genes have functions in lipid metabolism.

PPARγ is a member of the lipid-activated nuclear receptor superfamily and plays a recognized role in the transcriptional regulation of cellular proliferation, differentiation, and inflammation in addition to metabolic regulation of lipids and glucose [2, 3]. This receptor is regulated by fatty acid metabolites and acts as a transcription factor, forming heterodimers with the retinoid X receptor (RXR) and binding to specific PPAR response elements (PPREs) in the promoter regions of target genes [4, 5]. PPARs were originally described in adipocytes, monocytes, and macrophages [6, 7]. Since then, they have been described in other immune cell types of hematopoietic origin, including T lymphocytes, B lymphocytes, NK cells, dendritic cells, neutrophils, eosinophils, and mast cells, where a role for these receptors in inflammation and immunoregulation has been proposed [7–10]. However, the role of PPARs in the host immune responses to intracellular infectious agents is only now being recognized.

Herein, we focus on the role of PPARγ in intracellular bacterial infection. Specifically, we discuss the host response to Mycobacterium infection related to the regulation of PPARγ expression by mycobacteria and PPARγ-dependent effects on mycobacterial-induced modulation of host cell lipid metabolism and immune responses. Notably, PPARγ expression is highly upregulated during mycobacterial infection. Mycobacterial-induced PPARγ plays roles in host cell metabolism leading to increased lipid droplet formation and downregulates the host immune response to favor pathogen burden, thereby suggesting that pathogens may stimulate PPARγ activity as an escape mechanism.

2. Mycobacterium Infection Triggers Increased PPAR γ Expression

PPARγ is widely expressed in many cell types in different tissues, including in macrophages and dendritic cells in the lung [2, 11, 12]. Moreover, cytokines and pathogen-derived components may regulate PPARγ expression in cells of the immune system [13]. Recent studies have demonstrated that mycobacterial infection significantly increases PPARγ expression in human and mouse macrophages with important consequences for immune and metabolic host responses to infection [14, 15].

Infection of macrophages with either M. bovis bacillus Calmette-Guérin (BCG) or M. tuberculosis triggers a time-dependent increase in the expression of PPAR in macrophages in vitro [14, 15] and in vivo in the lung [16]. Increased PPARγ expression was apparent as early as 2 h after infection and reached maximal levels within 24 h after the infection. Of note, non-pathogenic, fast-growing M. smegmatis fails to induce PPARγ expression in macrophages, suggesting that PPARγ expression may be related to bacterial pathogenesis [14, 15].

The mechanisms involved in mycobacterial-induced PPARγ expression have recently been investigated. Interestingly, even infection with dead bacteria triggers PPARγ expression, as paraformaldehyde-killed M. tuberculosis or cell-wall components; mostly mannose-caped lipoarabinomannan (ManLAM) from either BCG or M. tuberculosis, are able to induce PPARγ expression, suggesting the role of pattern recognition receptors in the regulation of PPARγ [14–16].

During the infection of foam-like-macrophages, pathogenic mycobacteria trigger an innate immune response mediated by pathogen-associated molecular patterns (PAMPs), such as Toll-like receptors (TLR) and NOD-like receptors (NLRs). Recent reports indicate that NLR and TLR pathways are nonredundant in the recognition of M. tuberculosis and can synergize to induce a proinflammatory response [17].

TLRs represent some of the most important pattern recognition receptors (PRRs) that recognize mycobacterial products [18, 19]. Recognition through TLRs results in the rapid activation of signal-dependent transcription factors, including members of the nuclear factor-κB (NF-κB), activator protein 1 (AP1), and interferon regulatory factor (IRF) families [20, 21]. Activation of multiple TLRs, including TLR2, TLR4, and TLR9, as well as TLR6 and TLR1 when dimerized with TLR2, contributes to an efficient innate response against mycobacterial infection, resulting in inflammatory responses with cytokine production [18, 19, 22–24]. The NOD proteins are localized in the cytoplasm, and NOD2 has been implicated in the recognition of intracellular pathogens, such as mycobacteria [17, 25, 26]. NOD2 does not play a significant role in controlling M. tuberculosis growth during early infection [27], although NOD2 mRNA levels are increased in patients with tuberculosis [28]. In contrast, Brooks et al. [29] reported that NOD2 controls the growth of both M. tuberculosis and BCG in human macrophages, whereas it controls only BCG growth in murine macrophages. Collectively, these findings suggest that activation of different pathways is important and leads to different outcomes during mycobacterial infection.

The role of TLR in regulating PPARγ expression has been investigated. We demonstrated that PPARγ expression in macrophages infected with BCG or stimulated with ManLAM is requisitely dependent on TLR2 signaling [14]. However, the nonpathogenic M. smegmatis, a well-known TLR2 ligand, and the synthetic TLR2 ligand Pam3Cys fail to induce PPARγ expression in macrophages [14, 15], suggesting that coreceptors of TLR2 are required to induce PPARγ expression.

The TLR2 coreceptors and the downstream pathways involved in mycobacteria-induced PPARγ expression are currently unknown. Of note, Rajaram et al. [15] demonstrated that infection with virulent M. tuberculosis or the addition of ManLAM upregulates PPARγ expression independent of NF-κB in human macrophages.

3. PPARγ Regulates Host Immune Responses to Mycobacterial Infection

The host immune response to mycobacterial infection requires tightly balanced orchestration of both innate and adaptive immunity. The role of PPARγ in regulating the immune responses of murine and human macrophages to different species of Mycobacterium has been studied. PPARγ activation was demonstrated during infection by BCG [14, 16] and M. tuberculosis [15], as well as its major cell-wall immune-regulatory lipoglycan, namely, ManLAM [14, 15] that culminates with an anti-inflammatory response and downregulation of macrophage functions.

Of major interest during pathogen infection, PPARγ may repress target inflammatory genes, including proinflammatory cytokines and inducible NO synthase (iNOS) [30–32]. The molecular mechanisms of the negative regulation of inflammatory responses are executed, at least in part, by the ability of PPARγ to interfere with the activities of other signal-dependent transcription factors by transrepression [11]. PPARγ, which binds constitutively to DNA as a heterodimer with RXRs, functions as a transcriptional repressor through ligand-dependent transrepression of NF-κB target genes and may also function in the absence of ligand by interacting with corepressor complexes containing histone deacetylases (HDACs), nuclear-receptor corepressor (NcoR), or the silencing mediator of retinoic acid and thyroid-hormone receptor (SMRT) [30, 31, 33]. These protein complexes bind to the promoters of inflammatory genes and prevent the acetylation of histones and the aggregation of coactivator complexes. PPARγ downregulates proinflammatory gene expression by antagonizing the activity of transcription factors, including FOXP3, T-bet, and GATA-3, which are involved, respectively, in the regulation of inflammation and Th1 and Th2 immune responses [2, 3]. PPARγ serves also as a negative regulator of macrophage activation, altering the expression of many inflammatory genes [7, 9], modulating macrophage differentiation and activation through transrepression of the transcription factors STAT, AP-1, and NF-κB [32], and attenuating the respiratory burst [34]. The PPARγ ligands induce an allosteric change in PPARγ that results in covalent attachment of small ubiquitin-related modifier 1 (SUMO1) to the ligand-biding domain of PPARγ using the ubiquitin-conjugating enzyme 9 (UBC9) and the protein inhibitor of activated STAT1 (PIAS1) as the SUMO E2 and E3 ligases, respectively, for transcriptional repression [11]. Next, following sumoylation, PPARγ interacts with the nuclear corepressor (NCoR) complex to prevent signal-dependent recruitment of ubiquitin-conjugating enzymes (such as UBCH5) and the 19S proteasome components necessary for NCoR clearance [31]. As a result, the NCoR complex remains bound to the promoter region and exerts repressive activity to the nuclear transcription factors.

The function of PPARγ activation in the immune response to mycobacterial infection was investigated. PPARγ was shown to positively regulate prostaglandin (PG) E₂ production in BCG infected macrophages [14], a process potentiated by PPARγ agonists and inhibited by antagonists. Accordingly, PPARγ activation led to increased cyclooxygenase (COX) 2 expression [15] and PGE₂ production [35] in M. tuberculosis infected macrophages. Of note, PGE₂ is a potent immune modulator that downregulates Th1 responses and bactericidal activity toward intracellular organisms [36, 37].

The production of nitric oxide (NO) and other reactive nitrogen intermediates by innate immune cells is considered an effective host-defense mechanism against microbial pathogens, including mycobacterial infection. During infection, NO is produced by inducible NO synthase (iNOS) in response to bacterial components or a combination of proinflammatory cytokines, such as interferon (IFN)-γ, TNF-α, and IL-1β [38]. In most cells, iNOS transcription requires activation of NF-κB by TNF-α and IL-1β and activation of STAT-1 by IFN-γ [39, 40]. PPARγ has been implicated in the suppression of iNOS expression in macrophages [7, 32]. Synthetic PPARγ agonists promote PIAS1-dependent conjugation of SUMO1 to the PPARγ ligand-binding domain, preventing the signal-dependent ubiquitylation and the clearance of the NCoR complex required for full-gene activation and preventing the expression of iNOS [31]. Production of NO in macrophages is also regulated by the levels of arginases, which compete with iNOS for the substrate L-arginine, and catalyze the hydrolysis of L-arginine to L-ornithine and urea. Of note, PPARγ positively regulates arginase I expression in macrophages [41]. A role of PPARγ in modulating NO production during M. tuberculosis infection has been demonstrated. Silencing of PPARγ in M. tuberculosis infected macrophages significantly enhanced iNOS expression and NO production in these cells while inhibited arginase I expression, suggesting an endogenous role for PPARγ in the downmodulation of NO production during infection [35].

Infection in susceptible hosts are modulated by type 2 immune response with Th2 cells that produce IL-4 and IL-13 while protection is associated with type 1 immune response largely dependent of TNF-α and IFN-γ [42, 43]. IL-4 has been demonstrated as a key activator of PPARγ by regulating the induction of the 12/15-lipoxygenase-derived PPARγ ligands and through an interaction between PPARγ and signal transducer and activators of transcription 6 (STAT6) on promoters of PPARγ target genes [44, 45]. PPARγ activation suppresses the production of proinflammatory cytokines, and are critical for the formation, activation, and maintenance of alternatively activated macrophages [45]. Elevated PPARγ expression in human macrophages is one of the biological markers of IL-4/IL-13-mediated alternative activation. Conversely, deletion of PPARγ in alternatively activated macrophages leads to a Th1 pulmonary inflammatory response that favor intracellular pathogen killing [46]. PPARγ expression has been shown to be elevated in human alveolar macrophages, which are characterized as alternatively activated macrophages [15]. Moreover, markers of alternative macrophages are induced in M. tuberculosis-infected macrophages through PPARγ-dependent mechanisms [35]. In addition, the balance between the activities of NF-κB p65 and PPARγ has been demonstrated during mycobacterial challenge. Lagranderie et al. [16] showed that in nuclear lung-cell extracts 24 h after challenge with freeze-dried BCG, PPARγ expression increased and NF-κB p65 expression decreased, suggesting an association between the regulation of these two factors. Moreover, PPARγ knockdown in macrophages led to enhanced TNF-α and decreased IL-10 production by M. tuberculosis-infected macrophages [15, 35], indicating that PPARγ activation lead to an increase IL-10/TNF ratio creating an anti-inflammatory environment favorable for pathogen growth. Together, accumulating data on PPARγ-dependent effects on immune response during mycobacterial infection suggest that PPARγ induction is advantageous for this host-adapted intracellular pathogen within the lung microenvironment.

4. PPARγ Regulates Host Metabolism to Mycobacterial Infection

PPARγ has been shown to function as a key transcriptional regulator of lipid metabolism in macrophages and dendritic cells (DC) (for review, see [3]) through the direct regulation of genes participating in lipid uptake, transport, and storage [47–49]. Indeed, PPARγ is robustly expressed in macrophage-derived foam cells within atherosclerotic lesions, where it plays an important role in lipid homeostasis and metabolism [8, 32, 47, 50].

Pathogen-triggered dysregulation of host-cell lipid metabolism is emerging as a key feature in the pathogenesis of mycobacterial infection, as mycobacteria relies largely on host lipids for their survival and growth. Accumulating evidence suggests that modulation of host lipid metabolism through mycobacteria-induced lipid droplet formation is important in tuberculosis and leprosy. Foamy-like macrophages have been shown to play important roles in tuberculosis pathogenesis, both within the initial phases of macrophage infection and in granulomas [37, 51, 52]. In addition, lipid droplets formed in response to BCG and M. leprae constitute sites for eicosanoid synthesis, ultimately leading to increased production of PGE₂ by infected macrophages [14, 37, 53].

PPARγ is regulated and active in lipid droplet-enriched cells, and PPARγ may regulate processes associated with lipid-droplet formation in leukocytes during intracellular mycobacterial infection. In agreement with these results, the PPARγ agonist BRL49653 potentiates lipid droplet formation and PGE₂ production induced by a suboptimal dose of BCG. Conversely, pretreatment with an antagonist of PPARγ (GW9662) significantly inhibits BCG-induced lipid droplet formation and PGE₂ production [14], indicating the requirement for PPARγ signaling in lipid droplet biogenesis and further prostanoid production during BCG infection. The role of PPARγ activation in regulating lipid droplet biogenesis and PGE₂ production was subsequently confirmed in M. tuberculosis infected macrophages after PPARγ knockdown by RNAi [35].

The mechanisms involved in PPARγ-induced lipid droplet biogenesis in mycobacterial infection are still not completely understood. PPARγ-mediated expression of adipose differentiation-related protein (ADRP) has been described in different cells and conditions [54, 55]. ADRP is a member of the PAT family of proteins that plays an important role in adipocyte differentiation, lipolysis modulation, lipid droplet assembly, and biogenesis (reviewed in [56]). ADRP may act as a nucleation center for the assembly of nascent lipids [57, 58] and is also associated with the surface of lipid droplets in macrophages and Schwann cells during mycobacterial infection [37, 59], which is thought to play a major role in the maintenance of lipid storage and survival of pathogens. Increased expression of scavenger receptors, including MARCO, macrophage scavenger receptor (MRS), and CD36, has been observed in mycobacterial infection and leads to increased uptake and accumulation of host-derived oxidized lipids in infected cells [60]. Conversely, enhancing cholesterol efflux by liver X receptor (LXR) activation with the synthetic agonist GW3965 significantly decreased the cholesterol ester content of cells triggered by TLR pathways, including exposure to C. pneumonia and LPS [61]. In addition, treatment with the fatty acid synthase inhibitor C75, a PPARγ target, has been shown to inhibit significantly lipid droplet formation induced by mycobacterial infection with or without apoptotic cells, confirming the role of new lipid synthesis in lipid droplet biogenesis [62]. Thus, accumulating evidence indicates that mechanisms of increased lipogenesis, decreased lipid degradation, and regulation of lipid influx/efflux act synergistically to form lipid droplets during infection. Based on the different targets of PPARγ in lipid metabolism, it is conceivable that PPARγ operates at different levels to regulate lipid droplet biogenesis during infection.

5. Are There Roles for PPARγ in Mycobacterial Killing and Escape Mechanisms?

PPARγ has been extensively investigated for its role in many inflammatory diseases; however, its immunoregulatory roles in infectious and parasitic diseases have only recently gained recognition (review [63]).

As discussed above, increased PPARγ expression during mycobacterial infection is important for lipid metabolism and inflammatory responses of macrophages. Accumulating evidence has suggested that lipid droplet formation may favor intracellular survival and/or replication of M. tuberculosis, BCG and M. leprae in different models [37, 52, 59, 64]. Moreover, decreased production of proinflammatory cytokines and NO could also contribute to a favorable environment for pathogens, thereby suggesting that mycobacterial-induced PPARγ expression may act as an escape mechanism for this intracellular parasite.

The impact of PPARγ expression and activation in mycobacterial survival within macrophages has been investigated. The role of pharmacological inhibition of PPARγ in macrophage-induced mycobacterial killing was investigated. Pretreatment with the selective PPARγ antagonist, GW9662, significantly enhanced the capacity of macrophages to kill BCG, as determined by live/dead bacterial staining assessed by flow cytometry [14]. The role of PPARγ in modulating intracellular bacterial killing was later confirmed by silencing PPARγ in human macrophages and subsequently infecting the cells with M. tuberculosis. Following PPARγ knockdown, macrophages had significantly better ability to control M. tuberculosis growth, as assessed by colony forming assays [15]. The increased control of mycobacterial infection was concomitant with an increase in TNF-α production [15] and a decreased formation of lipid droplets [14], providing evidence that mycobacterial-induced PPARγ is an important mechanism in favoring mycobacterial growth in macrophages, at least partly through transcriptional regulation of inflammatory cytokines and lipid metabolism. This finding also suggests that lipid droplets may play a role in the pathogenesis of mycobacterial infection via PPARγ expression and activation dependent mechanisms.

Collectively, these findings indicate that mycobacteria utilize PPARγ signaling as an escape mechanism that enables survival within the hostile environments of macrophages.

6. Concluding Remarks and Perspectives

Recent studies have begun to shed light on the roles of PPARγ in mycobacterial infection. Studies on PPARγ expression and function have revealed that this transcription factor is highly upregulated during intracellular pathogen infection in which PPARγ plays roles in host cell metabolism and downregulating the host immune response to favor pathogen burden, thereby suggesting that pathogens may stimulate PPARγ activity as an escape mechanism (Figure 1). Accordingly, inhibition of PPARγ activity leads to increased mycobacterial killing and infection control, and as such, PPARγ is emerging as an attractive target candidate for therapeutic intervention strategies.

Figure 1: Model of PPARγ functions in mycobacterial infection. The activation of macrophage TLR2 signaling by M. tuberculosis, ManLAM, or M. bovis BCG results in the activation of PPARγ and NF-κB. The activation of PPARγ by mycobacterial infection induces lipid droplet formation, PGE₂ production and favors mycobacterial survival. Moreover, the PPARγ activation can down-modulate NF-κB activity inhibiting the proinflammatory cytokine production. Both inhibition of PPARγ with the selective antagonist GW9662 or PPARγ knockdown with siRNA result in a reduction of lipid droplet biogenesis and increased Mycobacterium killing by macrophages.

Although great advances in the understanding of the mechanisms of pathogen-induced PPARγ expression and its roles in lipid metabolism and inflammatory mediator production have been achieved, critical questions on intracellular pathogen infection remain. Future studies in animal models, as well as clinical studies, will be necessary to characterize the role of PPARγ in the pathogenesis of tuberculosis and as a target for therapeutic intervention.

Acknowledgments

The work of the authors is supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (CNPq, Brazil), PAPES-FIOCRUZ, the Fundação de Amparo à Pesquisa do Rio de Janeiro (FAPERJ, Brazil), and Guggenheim Foundation.

References

WHO, Global Tuberculosis Control, World Health Organization, Geneva, Switzerland, 2011.

L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.

I. Szatmari and L. Nagy, “Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function,” The EMBO Journal, vol. 27, no. 18, pp. 2353–2362, 2008.

S. A. Kliewer, K. Umesono, D. J. Mangelsdorf, and R. M. Evans, “Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling,” Nature, vol. 355, no. 6359, pp. 446–449, 1992.

B. P. Kota, T. H. W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005.

G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.

C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.

L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998.

M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, “The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function,” Journal of Leukocyte Biology, vol. 66, no. 5, pp. 733–739, 1999.

I. Szatmari, P. Gogolak, J. S. Im, B. Dezso, E. Rajnavolgyi, and L. Nagy, “Activation of PPARγ specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion,” Immunity, vol. 21, no. 1, pp. 95–106, 2004.

C. K. Glass and K. Saijo, “Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,” Nature Reviews Immunology, vol. 10, no. 5, pp. 365–376, 2010.

B. Nakken, T. Varga, I. Szatmari et al., “Peroxisome proliferator-activated receptor γ-regulated cathepsin D is required for lipid antigen presentation by dendritic cells,” The Journal of Immunology, vol. 187, no. 1, pp. 240–247, 2011.

A. Chawla, “Control of macrophage activation and function by PPARs,” Circulation Research, vol. 106, no. 10, pp. 1559–1569, 2010.

P. E. Almeida, A. R. Silva, C. M. Maya-Monteiro et al., “Mycobacterium bovis bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor γ expression and activation: functions in inflammation, lipid metabolism, and pathogenesis,” The Journal of Immunology, vol. 183, no. 2, pp. 1337–1345, 2009.

M. V. S. Rajaram, M. N. Brooks, J. D. Morris, J. B. Torrelles, A. K. Azad, and L. S. Schlesinger, “Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses,” The Journal of Immunology, vol. 185, no. 2, pp. 929–942, 2010.

M. Lagranderie, M. Abolhassani, J. A. J. Vanoirbeek et al., “Mycobacterium bovis bacillus Calmette-Guérin killed by extended freeze-drying targets plasmacytoid dendritic cells to regulate lung inflammation,” The Journal of Immunology, vol. 184, no. 2, pp. 1062–1070, 2010.

G. Ferwerda, S. E. Girardin, B. J. Kullberg et al., “NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis,” PLoS Pathogens, vol. 1, no. 3, article e34, pp. 0279–0285, 2005.

E. K. Jo, C. S. Yang, C. H. Choi, and C. V. Harding, “Intracellular signalling cascades regulating innate immune responses to Mycobacteria: branching out from Toll-like receptors,” Cellular Microbiology, vol. 9, no. 5, pp. 1087–1098, 2007.

B. Ryffel, M. Jacobs, S. Parida, T. Botha, D. Togbe, and V. Quesniaux, “Toll-like receptors and control of mycobacterial infection in mice,” Novartis Foundation Symposium, vol. 279, pp. 127–219, 2006.

M. Yamamoto, S. Sato, H. Hemmi et al., “Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway,” Science, vol. 301, no. 5633, pp. 640–643, 2003.

M. Yamamoto, S. Sato, K. Mori et al., “Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling,” The Journal of Immunology, vol. 169, no. 12, pp. 6668–6672, 2002.

T. K. Means, B. W. Jones, A. B. Schromm et al., “Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses,” The Journal of Immunology, vol. 166, no. 6, pp. 4074–4082, 2001.

T. K. Means, E. Lien, A. Yoshimura, S. Wang, D. T. Golenbock, and M. J. Fenton, “The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for toll-like receptors,” The Journal of Immunology, vol. 163, no. 12, pp. 6748–6755, 1999.

O. Takeuchi, S. Sato, T. Horiuchi et al., “Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins,” The Journal of Immunology, vol. 169, no. 1, pp. 10–14, 2002.

M. Divangahi, S. Mostowy, F. Coulombe et al., “NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity,” The Journal of Immunology, vol. 181, no. 10, pp. 7157–7165, 2008.

J. H. Leber, G. T. Crimmins, S. Raghavan, N. P. Meyer-Morse, J. S. Cox, and D. A. Portnoy, “Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen,” PLoS Pathogens, vol. 4, no. 1, article e6, 2008.

S. Gandotra, S. Jang, P. J. Murray, P. Salgame, and S. Ehrt, “Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis,” Infection and Immunity, vol. 75, no. 11, pp. 5127–5134, 2007.

S. Lala, K. Dheda, J. S. Chang et al., “The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis,” BMC Infectious Diseases, vol. 7, article 96, 2007.

M. N. Brooks, M. V. S. Rajaram, A. K. Azad et al., “NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages,” Cellular Microbiology, vol. 13, no. 3, pp. 402–418, 2011.

S. Ogawa, J. Lozach, C. Benner et al., “Molecular determinants of crosstalk between nuclear receptors and toll-like receptors,” Cell, vol. 122, no. 5, pp. 707–721, 2005.

G. Pascual, A. L. Fong, S. Ogawa et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ,” Nature, vol. 437, no. 7059, pp. 759–763, 2005.

M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.

C. H. Lee, K. Kang, I. R. Mehl et al., “Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2434–2439, 2006.

A. Von Knethen and B. Brüne, “Activation of peroxisome proliferator-activated receptor γ by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst,” The Journal of Immunology, vol. 169, no. 5, pp. 2619–2626, 2002.

S. Mahajan, H. K. Dkhar, V. Chandra, S. Dave, and R. Nanduri, “Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival,” The Journal of Immunology, vol. 188, no. 11, pp. 5593–5603, 2012.

M. Betz and B. S. Fox, “Prostaglandin E₂ inhibits production of Th1 lymphokines but not of Th2 lymphokines,” The Journal of Immunology, vol. 146, no. 1, pp. 108–113, 1991.

H. D'Avila, R. C. N. Melo, G. G. Parreira, E. Werneck-Barroso, H. C. Castro-Faria-Neto, and P. T. Bozza, “Mycobacterium bovis bacillus Calmette-Guérin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo,” The Journal of Immunology, vol. 176, no. 5, pp. 3087–3097, 2006.

S. Kwon and S. C. George, “Synergistic cytokine-induced nitric oxide production in human alveolar epithelial cells,” Nitric Oxide, vol. 3, no. 4, pp. 348–357, 1999.

R. W. Ganster, B. S. Taylor, L. Shao, and D. A. Geller, “Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8638–8643, 2001.

H. Kleinert, A. Pautz, K. Linker, and P. M. Schwarz, “Regulation of the expression of inducible nitric oxide synthase,” European Journal of Pharmacology, vol. 500, no. 1–3, pp. 255–266, 2004.

A. Gallardo-Soler, C. Gómez-Nieto, M. L. Campo et al., “Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-γ/δ-mediated effect that links lipid metabolism and immunity,” Molecular Endocrinology, vol. 22, no. 6, pp. 1394–1402, 2008.

M. Jacobs, D. Togbe, C. Fremond et al., “Tumor necrosis factor is critical to control tuberculosis infection,” Microbes and Infection, vol. 9, no. 5, pp. 623–628, 2007.

A. Dorhoi, S. T. Reece, and S. H. E. Kaufmann, “For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection,” Immunological Reviews, vol. 240, no. 1, pp. 235–251, 2011.

A. Szanto, B. L. Balint, Z. S. Nagy et al., “STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-regulated gene expression in macrophages and dendritic cells,” Immunity, vol. 33, no. 5, pp. 699–712, 2010.

F. O. Martinez, L. Helming, and S. Gordon, “Alternative activation of macrophages: an immunologic functional perspective,” Annual Review of Immunology, vol. 27, pp. 451–483, 2009.

A. Malur, A. J. Mccoy, S. Arce et al., “Deletion of PPARγ in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response,” The Journal of Immunology, vol. 182, no. 9, pp. 5816–5822, 2009.

A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001.

K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J. A. Gustafsson, “Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993.

H. Keller, A. Mahfoudi, C. Dreyer et al., “Peroxisome proliferator-activated receptors and lipid metabolism,” Annals of the New York Academy of Sciences, vol. 684, pp. 157–173, 1993.

P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998.

D. Ordway, M. Henao-Tamayo, I. M. Orme, and M. Gonzalez-Juarrero, “Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family,” The Journal of Immunology, vol. 175, no. 6, pp. 3873–3881, 2005.

P. Peyron, J. Vaubourgeix, Y. Poquet et al., “Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence,” PLoS Pathogens, vol. 4, no. 11, Article ID e1000204, 2008.

K. A. Mattos, H. D'Avila, L. S. Rodrigues et al., “Lipid droplet formation in leprosy: toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis,” Journal of Leukocyte Biology, vol. 87, no. 3, pp. 371–384, 2010.

S. E. Schadinger, N. L. R. Bucher, B. M. Schreiber, and S. R. Farmer, “PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes,” American Journal of Physiology, vol. 288, no. 6, pp. E1195–E1205, 2005.

P. Targett-Adams, M. J. McElwee, E. Ehrenborg, M. C. Gustafsson, C. N. Palmer, and J. McLauchlan, “A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein,” Biochimica et Biophysica Acta, vol. 1728, no. 1-2, pp. 95–104, 2005.

D. L. Brasaemle, “The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis,” Journal of Lipid Research, vol. 48, no. 12, pp. 2547–2559, 2007.

D. N. Gross, H. Miyoshi, T. Hosaka et al., “Dynamics of lipid droplet-associated proteins during hormonally stimulated lipolysis in engineered adipocytes: stabilization and lipid droplet binding of adipocyte differentiation-related protein/adipophilin,” Molecular Endocrinology, vol. 20, no. 2, pp. 459–466, 2006.

S. M. Wang, R. D. Hwang, A. S. Greenberg, and H. L. Yeo, “Temporal and spatial assembly of lipid droplet-associated proteins in 3T3-L1 preadipocytes,” Histochemistry and Cell Biology, vol. 120, no. 4, pp. 285–292, 2003.

K. A. Mattos, F. A. Lara, V. G. C. Oliveira et al., “Modulation of lipid droplets by Mycobacterium leprae in Schwann cells: a putative mechanism for host lipid acquisition and bacterial survival in phagosomes,” Cellular Microbiology, vol. 13, no. 2, pp. 259–273, 2011.

D. Cruz, A. D. Watson, C. S. Miller et al., “Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy,” The Journal of Clinical Investigation, vol. 118, no. 8, pp. 2917–2928, 2008.

F. Cao, A. Castrillo, P. Tontonoz, F. Re, and G. I. Byrne, “Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by toll-like receptor 2,” Infection and Immunity, vol. 75, no. 2, pp. 753–759, 2007.

H. D'Avila, N. R. Roque, R. M. Cardoso, H. C. Castro-Faria-Neto, R. C. N. Melo, and P. T. Bozza, “Neutrophils recruited to the site of Mycobacterium bovis BCG infection undergo apoptosis and modulate lipid body biogenesis and prostaglandin E2 production by macrophages,” Cellular Microbiology, vol. 10, no. 12, pp. 2589–2604, 2008.

M. M. Chan, K. W. Evans, A. R. Moore, and D. Fong, “Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 828951, p. 9, 2010.

K. A. Mattos, V. G. Oliveira, D. 'Avila H, L. S. Rodrigues, and R. O. Pinheiro, “TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence,” The Journal of Immunology, vol. 187, pp. 2548–2558.